{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:09:51Z","timestamp":1793196591394,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Hainan Provincial Natural Science Foundation of China","award":["823QN372"],"award-info":[{"award-number":["823QN372"]}]},{"name":"Hainan Provincial Natural Science Foundation of China","award":["821RC736"],"award-info":[{"award-number":["821RC736"]}]},{"name":"Hainan Province Science and Technology Special Fund","award":["ZDYF2022SHFZ057"],"award-info":[{"award-number":["ZDYF2022SHFZ057"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00535-023-02042-2","type":"journal-article","created":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T05:01:22Z","timestamp":1696136482000},"page":"1167-1177","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study"],"prefix":"10.1007","volume":"58","author":[{"given":"Ying-Ying","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Lian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Wu","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang-Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Xia","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6300-1460","authenticated-orcid":false,"given":"Pei-Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,1]]},"reference":[{"key":"2042_CR1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1053\/j.gastro.2017.04.022","volume":"153","author":"JKY Hooi","year":"2017","unstructured":"Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153:420\u20139.","journal-title":"Gastroenterology"},{"issue":"Suppl","key":"2042_CR2","first-page":"1","volume":"22","author":"C Burucoa","year":"2017","unstructured":"Burucoa C, Axon A. Epidemiology of Helicobacter pylori infection. Helicobacter. 2017;22(Suppl):1.","journal-title":"Helicobacter"},{"issue":"12","key":"2042_CR3","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1056\/NEJMcp1710945","volume":"380","author":"SE Crowe","year":"2019","unstructured":"Crowe SE. Helicobacter pylori infection. N Engl J Med. 2019;380(12):1158\u201365.","journal-title":"N Engl J Med"},{"key":"2042_CR4","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1136\/gutjnl-2022-327745","volume":"71","author":"P Malfertheiner","year":"2022","unstructured":"Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report. Gut. 2022;71:1724\u201362.","journal-title":"Gut"},{"key":"2042_CR5","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1097\/CM9.0000000000002546","volume":"135","author":"L Zhou","year":"2022","unstructured":"Zhou L, Lu H, Song Z, et al. 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment. Chin Med J (Engl). 2022;135:2899\u2013910.","journal-title":"Chin Med J (Engl)"},{"key":"2042_CR6","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/gut.2009.192757","volume":"59","author":"DY Graham","year":"2010","unstructured":"Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59:1143\u201353.","journal-title":"Gut"},{"key":"2042_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12762","volume":"25","author":"Z Song","year":"2020","unstructured":"Song Z, Zhou L, Xue Y, et al. A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: a randomized trial. Helicobacter. 2020;25: e12762.","journal-title":"Helicobacter"},{"key":"2042_CR8","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1136\/gutjnl-2021-324032","volume":"70","author":"F Megraud","year":"2021","unstructured":"Megraud F, Bruyndonckx R, Coenen S, et al. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut. 2021;70:1815\u201322.","journal-title":"Gut"},{"key":"2042_CR9","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1053\/j.gastro.2020.11.059","volume":"160","author":"SC Shah","year":"2021","unstructured":"Shah SC, Iyer PG, Moss SF. AGA clinical practice update on the management of refractory Helicobacter pylori infection: expert review. Gastroenterology. 2021;160:1831\u201341.","journal-title":"Gastroenterology"},{"key":"2042_CR10","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.3748\/wjg.v23.i16.2854","volume":"23","author":"N Arslan","year":"2017","unstructured":"Arslan N, Y\u0131lmaz \u00d6, Demiray-G\u00fcrb\u00fcz E. Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection. World J Gastroenterol. 2017;23:2854\u201369.","journal-title":"World J Gastroenterol"},{"key":"2042_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12692","volume":"25","author":"CP Gao","year":"2020","unstructured":"Gao CP, Zhang D, Zhang T, et al. PPI-amoxicillin dual therapy for Helicobacter pylori infection: an update based on a systematic review and meta-analysis. Helicobacter. 2020;25: e12692.","journal-title":"Helicobacter"},{"key":"2042_CR12","first-page":"137","volume":"42","author":"YY Han","year":"2022","unstructured":"Han YY, Fang D, Guan JL, et al. Research and progress of amoxicillin and proton pump inhibitor dual therapy for Helicobacter pylori infection. Chin J Dig. 2022;42:137\u201340.","journal-title":"Chin J Dig"},{"key":"2042_CR13","first-page":"491","volume":"88","author":"J Labenz","year":"1993","unstructured":"Labenz J, Gyenes E, R\u00fchl GH, et al. Omeprazole plus amoxicillin: efficacy of various treatment regimens to eradicate Helicobacter pylori. Am J Gastroenterol. 1993;88:491\u20135.","journal-title":"Am J Gastroenterol"},{"key":"2042_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2015.18","volume":"6","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese\/non-Japanese Subjects. Clin Transl Gastroenterol. 2015;6: e94.","journal-title":"Clin Transl Gastroenterol"},{"key":"2042_CR15","doi-asserted-by":"publisher","first-page":"9781212","DOI":"10.1155\/2019\/9781212","volume":"2019","author":"QJ Lyu","year":"2019","unstructured":"Lyu QJ, Pu QH, Zhong XF, et al. Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis of randomized clinical trials. Biomed Res Int. 2019;2019:9781212.","journal-title":"Biomed Res Int"},{"key":"2042_CR16","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/jgh.15837","volume":"37","author":"X Hou","year":"2022","unstructured":"Hou X, Meng F, Wang J, et al. Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients. J Gastroenterol Hepatol. 2022;37:1275\u201383.","journal-title":"J Gastroenterol Hepatol"},{"key":"2042_CR17","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1111\/jgh.15917","volume":"37","author":"Y Ouyang","year":"2022","unstructured":"Ouyang Y, Wang M, Xu YL, et al. Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2022;37:1666\u201372.","journal-title":"J Gastroenterol Hepatol"},{"key":"2042_CR18","doi-asserted-by":"publisher","first-page":"16029","DOI":"10.3748\/wjg.v20.i43.16029","volume":"20","author":"CH Kuo","year":"2014","unstructured":"Kuo CH, Lu CY, Shih HY, et al. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol. 2014;20:16029\u201336.","journal-title":"World J Gastroenterol"},{"key":"2042_CR19","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/phar.2662","volume":"42","author":"JL Guan","year":"2022","unstructured":"Guan JL, Hu YL, An P, et al. Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: an open-label, multicenter, randomized controlled trial. Pharmacotherapy. 2022;42:224\u201332.","journal-title":"Pharmacotherapy"},{"key":"2042_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12922","volume":"27","author":"YY Han","year":"2022","unstructured":"Han YY, Long H, Lin Y, et al. Optimized dual therapy for treatment-naive patients of Helicobacter pylori infection: a large-scale prospective, multicenter, open-label, randomized controlled study. Helicobacter. 2022;27: e12922.","journal-title":"Helicobacter"},{"key":"2042_CR21","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1046\/j.1365-2036.2000.00840.x","volume":"14","author":"K Adachi","year":"2000","unstructured":"Adachi K, Katsube T, Kawamura A, et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther. 2000;14:1259\u201366.","journal-title":"Aliment Pharmacol Ther"},{"key":"2042_CR22","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1128\/AAC.44.2.458-461.2000","volume":"44","author":"Y Kawakami","year":"2000","unstructured":"Kawakami Y, Akahane T, Yamaguchi M, et al. In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother. 2000;44:458\u201361.","journal-title":"Antimicrob Agents Chemother"},{"key":"2042_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12717","volume":"25","author":"W Gao","year":"2020","unstructured":"Gao W, Ye H, Deng X, et al. Rabeprazole-amoxicillin dual therapy as first-line treatment for H pylori eradication in special patients: a retrospective, real-life study. Helicobacter. 2020;25: e12717.","journal-title":"Helicobacter"},{"key":"2042_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12876","volume":"27","author":"QQ Shao","year":"2022","unstructured":"Shao QQ, Yu XC, Yu M, et al. Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: a single-center, prospective, open-label, randomized-controlled trial. Helicobacter. 2022;27: e12876.","journal-title":"Helicobacter"},{"key":"2042_CR25","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3748\/wjg.v20.i3.665","volume":"20","author":"A Federico","year":"2014","unstructured":"Federico A, Gravina AG, Miranda A, et al. Eradication of Helicobacter pylori infection: which regimen first? World J Gastroenterol. 2014;20:665\u201372.","journal-title":"World J Gastroenterol"},{"key":"2042_CR26","doi-asserted-by":"publisher","first-page":"e12597","DOI":"10.1111\/hel.12597","volume":"24","author":"M Kato","year":"2019","unstructured":"Kato M, Ota H, Okuda M, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised edition. Helicobacter. 2019;24:e12597.","journal-title":"Helicobacter"},{"key":"2042_CR27","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1136\/gutjnl-2020-322368","volume":"69","author":"JM Liou","year":"2020","unstructured":"Liou JM, Malfertheiner P, Lee YC, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020;69:2093\u2013112.","journal-title":"Gut"},{"key":"2042_CR28","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00535-020-01709-4","volume":"55","author":"T Gotoda","year":"2020","unstructured":"Gotoda T, Kusano C, Suzuki S, et al. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-na\u00efve cohort of junior high school students in Japan. J Gastroenterol. 2020;55:969\u201376.","journal-title":"J Gastroenterol"},{"key":"2042_CR29","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/gutjnl-2019-319954","volume":"69","author":"S Suzuki","year":"2020","unstructured":"Suzuki S, Gotoda T, Kusano C, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69:1019\u201326.","journal-title":"Gut"},{"key":"2042_CR30","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.gtc.2010.08.007","volume":"39","author":"T Furuta","year":"2010","unstructured":"Furuta T, Graham DY. Pharmacologic aspects of eradication therapy for Helicobacter pylori infection. Gastroenterol Clin North Am. 2010;39:465\u201380.","journal-title":"Gastroenterol Clin North Am"},{"key":"2042_CR31","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1159\/000502287","volume":"101","author":"T Furuta","year":"2020","unstructured":"Furuta T, Yamade M, Kagami T, et al. Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori. Digestion. 2020;101:743\u201351.","journal-title":"Digestion"},{"key":"2042_CR32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jgh3.12852","volume":"7","author":"S Sue","year":"2022","unstructured":"Sue S, Kondo M, Sato T, et al. Vonoprazan and high-dose amoxicillin dual therapy for Helicobacter pylori first-line eradication: a single-arm, interventional study. JGH Open. 2022;7:55\u201360.","journal-title":"JGH Open"},{"key":"2042_CR33","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1111\/jgh.15572","volume":"36","author":"T Horii","year":"2021","unstructured":"Horii T, Suzuki S, Takano C, et al. Lower impact of vonoprazan-amoxicillin dual therapy on gut microbiota for Helicobacter pylori eradication. J Gastroenterol Hepatol. 2021;36:3314\u201321.","journal-title":"J Gastroenterol Hepatol"},{"key":"2042_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12896","volume":"27","author":"Y Hu","year":"2022","unstructured":"Hu Y, Xu X, Ouyang YB, et al. Optimization of vonoprazan-amoxicillin dual therapy for eradicating Helicobacter pylori infection in China: a prospective, randomized clinical pilot study. Helicobacter. 2022;27: e12896.","journal-title":"Helicobacter"},{"key":"2042_CR35","doi-asserted-by":"publisher","first-page":"1049908","DOI":"10.3389\/fimmu.2022.1049908","volume":"13","author":"Y Hu","year":"2023","unstructured":"Hu Y, Xu X, Liu XS, et al. Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: a prospective, open-labeled, randomized non-inferiority clinical study. Front Immunol. 2023;13:1049908.","journal-title":"Front Immunol"},{"key":"2042_CR36","doi-asserted-by":"publisher","first-page":"627","DOI":"10.14309\/ajg.0000000000002086","volume":"118","author":"HS Qian","year":"2023","unstructured":"Qian HS, Li WJ, Dang YN, et al. Ten-day vonoprazan-amoxicillin dual therapy as a first-line treatment of Helicobacter pylori infection compared with bismuth-containing quadruple therapy. Am J Gastroenterol. 2023;118:627\u201334.","journal-title":"Am J Gastroenterol"},{"key":"2042_CR37","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/MEG.0000000000001646","volume":"32","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhu YJ, Zhao Z, et al. Efficacy of modified esomeprazole-amoxicillin dual therapies for Helicobacter pylori infection: an open-label, randomized trial. Eur J Gastroenterol Hepatol. 2020;32:563\u20138.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2042_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12833","volume":"26","author":"PY Zou","year":"2021","unstructured":"Zou PY, Hu J, Zhao JT, et al. 10-Day and 14-day high-dose dual therapy for the treatment of Helicobacter pylori: a propensity score matching analysis. Helicobacter. 2021;26: e12833.","journal-title":"Helicobacter"},{"key":"2042_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12788","volume":"26","author":"H Eto","year":"2021","unstructured":"Eto H, Suzuki S, Kusano C, et al. Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy. Helicobacter. 2021;26: e12788.","journal-title":"Helicobacter"},{"key":"2042_CR40","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/1751-2980.12367","volume":"17","author":"S Upala","year":"2016","unstructured":"Upala S, Jaruvongvanich V, Riangwiwat T, et al. Association between Helicobacter pylori infection and metabolic syndrome: a systematic review and meta-analysis. J Dig Dis. 2016;17:433\u201340.","journal-title":"J Dig Dis"},{"key":"2042_CR41","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.diabres.2014.07.009","volume":"106","author":"C Horikawa","year":"2014","unstructured":"Horikawa C, Kodama S, Fujihara K, et al. High risk of failing eradication of Helicobacter pylori in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2014;106:81\u20137.","journal-title":"Diabetes Res Clin Pract"},{"key":"2042_CR42","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3945\/ajcn.116.144873","volume":"106","author":"H Ikezaki","year":"2017","unstructured":"Ikezaki H, Furusyo N, Jacques PF, et al. Higher dietary cholesterol and \u03c9-3 fatty acid intakes are associated with a lower success rate of Helicobacter pylori eradication therapy in Japan. Am J Clin Nutr. 2017;106:581\u20138.","journal-title":"Am J Clin Nutr"},{"key":"2042_CR43","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S2468-1253(17)30219-4","volume":"2","author":"YT Kuo","year":"2017","unstructured":"Kuo YT, Liou JM, El-Omar EM, et al. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:707\u201315.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2042_CR44","doi-asserted-by":"publisher","first-page":"780.e5","DOI":"10.1016\/j.cmi.2017.11.010","volume":"24","author":"DS Liu","year":"2018","unstructured":"Liu DS, Wang YH, Zeng ZR, et al. Primary antibiotic resistance of Helicobacter pylori in Chinese patients: a multiregion prospective 7-year study. Clin Microbiol Infect. 2018;24:780.e5-780.e8.","journal-title":"Clin Microbiol Infect"},{"key":"2042_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12947","volume":"28","author":"W Gao","year":"2023","unstructured":"Gao W, Xu Y, Liu J, et al. A real-world exploratory study on the feasibility of vonoprazan and tetracycline dual therapy for the treatment of Helicobacter pylori infection in special populations with penicillin allergy or failed in previous amoxicillin-containing therapies. Helicobacter. 2023;28: e12947.","journal-title":"Helicobacter"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-023-02042-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-023-02042-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-023-02042-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T11:02:02Z","timestamp":1700391722000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-023-02042-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,1]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2042"],"URL":"https:\/\/doi.org\/10.1007\/s00535-023-02042-2","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,1]]},"assertion":[{"value":"12 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Institutional Ethics Board of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval statement"}},{"value":"The trial was registered in the Chinese Clinical Trials Registration (chictr.org.cn: ChiCTR2200059309).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}},{"value":"All patients agreed to participate in this study and gave informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent statement"}}]}}